Condition
B-Cell Non-Hodgkin Lymphoma-Recurrent
Total Trials
3
Recruiting
3
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 1 (2)
Trial Status
Recruiting3
Clinical Trials (3)
Showing 3 of 3 trials
NCT06209619Phase 1RecruitingPrimary
CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma
NCT06618313Not ApplicableRecruitingPrimary
One Trial to Evaluate the Safety, Tolerability and Efficacy of JCXH-213 in Patients With r/r B-NHL
NCT06395870Phase 1RecruitingPrimary
Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Showing all 3 trials